Silver Book Fact

A year-long study of patients with congestive heart failure found that increased use of medicines increased pharmaceutical costs by 60%; however, hospital costs declined by 78%, producing a net savings of $9.3 million. The ability of patients to perform activities of daily living went up 15% and the death rate dropped from an expected 25% to 10%.

Managed Healthcare. Provide Education About Congestive Heart Failure and Pump Up Your Savings; Mar-1998:42-4

Reference

Title
Provide Education About Congestive Heart Failure and Pump Up Your Savings
Publication Date
Mar-1998
Authors
Managed Healthcare
Volume & Issue
Volume 8, Issue 4
Pages
42-4

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • About 2/3 of reduced mortality from cardiovascular disease is a result of medical interventions.  
  • The projected economic value of eliminating deaths from stroke is $7.6 trillion.  
  • TAVR Success in sSAS Patients
    A study of severe symptomatic aortic stenosis (sSAS) patients who received transcatheter aortic valve replacement (TAVR) found 30-day mortality of 2.2% for those who were high risk of surgical mortality/inoperable,…  
  • Cost-effectiveness of TAVR in sSAS patients
    Patients with severe symptomatic aortic stenosis (sSAS) considered to be at high surgical risk who underwent transcatheter aortic valve replacement (TAVR) experienced lifetime incremental cost-effectiveness ratios of $55,090 per QALY…  
  • Undertreatment of patients with sSAS
    AS is often undertreated — one study found that 56% of severe symptomatic aortic stenosis (sSAS) patients referred to a cardiothoracic surgeon were not operated on.